H. Klamová

发表

A short note on the nuclear diameter in human early granulocytic progenitors

K. Smetana, D. Mikulenková, H. Klamová, 2006, Hematology.

The Relationship of Kynurenine and Neopterin Levels and Their Association with a Selection of Other Immune Markers in Chronic Myeloid Leukaemia Patients.

H. Klamová, V. Vonka, M. Petráčková, 2016, Folia biologica.

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

T. Pavlík, L. Dušek, H. Klamová, 2011, BMC medical research methodology.

Imatinib mesylate affects tyrosine kinase activity in both leukemic and normal primary mononuclear blood cells

H. Klamová, K. Kuželová, I. Marinov, 2006 .

AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome

H. Klamová, J. Koblihova, K. Šrůtová, 2018, PloS one.

Heterochromatin density (condensation) during cell differentiation and maturation using the human granulocytic lineage of chronic myeloid leukaemia as a convenient model.

K. Smetana, D. Mikulenková, H. Klamová, 2011, Folia biologica.

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

D. Colomer, I. Glauche, T. Lion, 2022, Leukemia.

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining

T. Kalina, V. Kanderova, O. Hrusak, 2021, Frontiers in Oncology.

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

D. Colomer, I. Glauche, T. Lion, 2022, Leukemia.

Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment

H. Klamová, V. Vonka, Z. Humlová, 2010, Clinical & developmental immunology.

Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.

H. Klamová, K. Michalová, M. Jarošová, 2004, Leukemia research.

Hsp90 - a potential prognostic marker in CML.

H. Klamová, J. Moravcová, M. Žáčková, 2013, Blood cells, molecules & diseases.

Dominant Nucleolus in the Progenitor Cell Using Human Bone Marrow Erythroid and Granulocytic Cell Lineages as a Model. A Morphological and Cytochemical Note.

K. Smetana, D. Mikulenková, H. Klamová, 2020, Folia biologica.

Nucleolar and cytoplasmic RNA density-concentration in leukemia granulocytic progenitors in human bone marrow biopsies: A short cytochemical note.

K. Smetana, D. Mikulenková, H. Klamová, 2011, Acta Histochemica.

The translocation of AgNORs in large nucleoli of early granulocyte progenitors in patients suffering from chronic phase of chronic myeloid leukaemia

K. Smetana, D. Mikulenková, H. Klamová, 2009 .

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials

L. Dušek, H. Klamová, J. Mužík, 2013, Leukemia & lymphoma.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

S. Mustjoki, H. Dombret, M. Höglund, 2008, Blood.

CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.

H. Klamová, J. Březinová, J. Čermák, 2008, Blood cells, molecules & diseases.

Intranucleolar translocation of AgNORs in early granulocytic precursors in chronic myeloid leukaemia and K 562 cells.

K. Smetana, H. Klamová, Z. Hrkal, 2005, Folia biologica.

To the intranucleolar translocation of AgNORs in leukemic early granulocytic and plasmacytic precursors

K. Smetana, H. Klamová, Z. Hrkal, 2005, Histochemistry and Cell Biology.

Intracellular Cytokines Produced by Stimulated CD3+ Cells from Chronic Myeloid Leukemia Patients

H. Klamová, V. Vonka, M. Petráčková, 2017, Acta Haematologica.

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

H. Klamová, Tereza Nečasová, J. Mayer, 2020, Leukemia & lymphoma.

Gene expression profiles of two accelerations in a CML patient.

H. Klamová, J. Moravcová, K. Fišer, 2006, Leukemia research.

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels

L. Dušek, H. Klamová, M. Karas, 2013, Cancer medicine.

Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

L. Dušek, H. Klamová, J. Březinová, 2011, American journal of hematology.

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.

H. Klamová, J. Moravcová, D. Dvořáková, 2010, Experimental hematology.

Control genes in international standardization of real-time RT-PCR for BCR-ABL.

H. Klamová, J. Moravcová, K. Polakova, 2009, Leukemia research.

central nervous system Philadelphia chromosomepositive leukemia Dasatinib crosses the blood-brain barrier and is an efficient therapy for

S. Mustjoki, H. Dombret, M. Höglund, 2009 .

The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.

H. Klamová, Z. Zemanová, J. Moravcová, 2007, Leukemia research.

A short cytochemical note on the nucleolar and cytoplasmic RNA concentration in differentiating cells represented by human erythroblasts.

K. Smetana, D. Mikulenková, H. Klamová, 2010, Acta histochemica.

Are microproerythroblasts in human bone marrow real or artefacts? A cytochemical note.

K. Smetana, H. Klamová, I. Jirásková, 2005, Acta histochemica.

Nucleoli in Human Early Erythroblasts ( K 2 , K 1 , K 1 / 2 Cells ) ( nucleoli / human early erythroblasts )

K. Smetana, H. Klamová, I. Jirásková, 2005 .

Unusually Long Survival of a 67-Year-Old Patient with Near-Tetraploid Acute Myeloid Leukemia M0 without Erythroblastic and Megakaryocytic Dysplasia

J. Jelinek, H. Klamová, Z. Zemanová, 2011, Acta Haematologica.

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

H. Klamová, E. Faber, J. Mayer, 2010, American journal of hematology.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

M. Baccarani, G. Rosti, G. Martinelli, 2016, Oncotarget.

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

H. Klamová, J. Březinová, K. Michalová, 2010, Neoplasma.

BCR-ABL mutations in chronic myeloid leukemia–Not only detection

H. Klamová, Z. Zemanová, J. Moravcová, 2008, Leukemia & lymphoma.

[Use of photodynamic therapy for elimination of residual leukemic cells in autologous transplants of hematopoietic progenitor cells].

H. Klamová, J. Bartošová, I. Marinov, 2002, Casopis lekaru ceskych.

Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia.

K. Zemanová, H. Klamová, R. Tachezy, 2017, Oncology reports.

Inhibition of Casein Kinase 2 induces cell death in chronic myelogenous leukemia cells resistant to tyrosine kinase inhibitors

H. Klamová, J. Březinová, Š. Ransdorfová, 2021, bioRxiv.

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

R. Hercog, V. Beneš, H. Klamová, 2017, Journal of Experimental & Clinical Cancer Research.

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain.

H. Klamová, J. Moravcová, K. Polakova, 2008, Leukemia research.

Perinucleolar heterochromatin during the cell differentiation using human leukemic neutrophils as a convenient model

K. Smetana, D. Mikulenková, H. Klamová, 2015 .

P230 BCR/ABL protein may be associated with an acute leukaemia phenotype

H. Klamová, G. Saglio, Z. Zemanová, 1998, British journal of haematology.

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

H. Klamová, S. Soverini, E. Faber, 2016, PloS one.

Kynurenine and uric acid levels in chronic myeloid leukemia patients

H. Klamová, V. Vonka, M. Petráčková, 2015, Oncoimmunology.

To the approximate size of the nuclear region occupied by nucleolar bodies during cell differentiation and maturation using the human leukemic granulocytic lineage as a convenient model.

K. Smetana, D. Mikulenková, H. Klamová, 2019, Physiological research.

On the nucleolar size and density in human early granulocytic progenitors, myeloblasts.

K. Smetana, D. Mikulenková, H. Klamová, 2006, European journal of histochemistry : EJH.

Nucleoli in Human Early Granulocytic Precursors ( nucleolar size / human early granulocytic precursors )

K. Smetana, D. Mikulenková, H. Klamová, 2006 .

Nucleoli in human early erythroblasts (K2, K1, K1/2 cells).

K. Smetana, H. Klamová, I. Jirásková, 2005, Folia biologica.

The number of nucleoli expressed by the nucleolar coefficient in the granulopoietic bone marrow compartment in non-leukemic persons and patients suffering from chronic myeloid leukemia.

K. Smetana, H. Klamová, I. Jirásková, 1998, Haematologica.

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.

M. Iacono, A. Kohlmann, T. Haferlach, 2013, Blood.

ABL populations by ultra-deep sequencing of the resistant − Unraveling the complexity of tyrosine kinase inhibitor

M. Iacono, A. Kohlmann, T. Haferlach, 2013 .

To the density and distribution of heterochromatin in differentiating, maturing and apoptotic cells represented by granulocytic, lymphocytic and erythrocytic precursors.

K. Smetana, H. Klamová, Z. Hrkal, 2008, Folia biologica.

The heterochromatin condensation state in central nuclear regions of individual granulocytes

K. Smetana, D. Mikulenková, H. Klamová, 2013 .

Expression patterns of microRNAs associated with CML phases and their disease related targets

H. Klamová, T. Stopka, J. Moravcová, 2011, Molecular Cancer.

Complex chromosomal rearrangements in patients with chronic myeloid leukemia.

H. Klamová, Z. Zemanová, J. Březinová, 2006, Cancer genetics and cytogenetics.

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

E. Koritáková, H. Klamová, E. Faber, 2018, American journal of hematology.

Two subpopulations of progenitors of leukemic lineages in human myeloid leukemias exhibit different heterochromatin condensation state in central and peripheral nuclear regions (A morphological note with additional original observations)

K. Smetana, D. Mikulenková, H. Klamová, 2020, Integrative Cancer Science and Therapeutics.

WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance.

H. Klamová, E. Otáhalová, C. Haškovec, 2009, Neoplasma.

Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.

H. Klamová, J. Moravcová, P. Cetkovský, 2009, Leukemia research.

Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation

H. Klamová, R. Brdička, A. Kračmarová, 2007, Leukemia & lymphoma.

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.

H. Klamová, K. Indrák, J. Mužík, 2011, Neoplasma.

Gene Expression Profiling in Chronic Myeloid Leukemia Patients Treated with Hydroxyurea

H. Klamová, R. Brdička, H. Bruchova, 2002, Leukemia & lymphoma.

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

T. Pavlík, L. Dušek, H. Klamová, 2013, American journal of hematology.

Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo.

H. Klamová, K. Kuželová, J. Moravcová, 2016, Blood cells, molecules & diseases.

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

I. Glauche, H. Klamová, N. Cross, 2020, Leukemia.

The DNA chromatin condensation expressed by the image optical density of chromosomes and heterochromatin in proliferating single human leukemic granulocytic progenitors

K. Smetana, D. Mikulenková, H. Klamová, 2012 .

Expression of cytokine receptors on different myeloid leukemic cells.

H. Klamová, J. Starý, M. Filipec, 1998, Neoplasma.

Morphometric and Densitometric Analysis of Heterochromatin during Cell Differentiation Using the Leukaemic Granulocytic Lineage as a Convenient Model.

K. Smetana, D. Mikulenková, H. Klamová, 2017, Folia biologica.

Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia.

H. Klamová, J. Moravcová, S. Nádvorníková, 1999, Blood.

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

A. Kohlmann, T. Haferlach, M. Baccarani, 2015, Journal of Cancer Research and Clinical Oncology.

Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs.

H. Klamová, J. Moravcová, J. Schwarz, 2012, Blood cells, molecules & diseases.

Effect of the duration and quality of peripheral blood sample storage on the results of qualitative and quantitative BCR-ABL transcript analyses in patients with CML.

H. Klamová, J. Moravcová, A. Broučková, 2011, Leukemia research.

Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells

H. Klamová, N. Čuřík, J. Koblihova, 2021, Leukemia.

Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment.

H. Klamová, K. Michalová, M. Píšacka, 2006, Folia biologica.

Occurrence of cytokine receptors on different lymphoid leukaemic cells

H. Klamová, J. Starý, M. Filipec, 1999, European journal of haematology.

Targeting of gene expression by siRNA in CML primary cells

H. Klamová, R. Brdička, H. Bruchova, 2007, Molecular Biology Reports.

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

H. Klamová, J. Mužík, J. Dyr, 2014, Hematological oncology.

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing

H. Klamová, J. Zuna, S. Soverini, 2015, Molecular Cancer.

N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia.

H. Klamová, J. Moravcová, J. Schwarz, 2012, Leukemia research.

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

H. Klamová, J. Mayer, Z. Ráčil, 2011, International journal of hematology.

Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications

M. Baccarani, G. Rosti, G. Martinelli, 2012 .

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

H. Klamová, D. Perrotti, R. Trotta, 2018, Haematologica.

MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?

H. Klamová, J. Moravcová, Tereza Lopotová, 2011, Leukemia research.

Selective destruction of leukaemic cells by photo-activation of 5-aminolaevulinic acid-induced protoporphyrin-IX.

H. Klamová, J. Bartošová, O. Fuchs, 1998, Journal of photochemistry and photobiology. B, Biology.

Differential Expression of miRNAs during the Course of Chronic Myeloid Leukemia.

H. Klamová, J. Moravcová, K. Polakova, 2008 .

To the morphological heterochromatin condensation state in granulocytic progenitors - myeloblasts - in patients suffering from the myelodysplastic syndrome and acute myeloblastic leukemia

K. Smetana, D. Mikulenková, H. Klamová, 2020, Hematology and Medical Oncology.

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing

H. Klamová, J. Zuna, S. Soverini, 2015, Molecular Cancer.

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.

H. Klamová, Z. Zemanová, J. Moravcová, 2005, Leukemia research.

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

R. Hercog, V. Beneš, H. Klamová, 2017, Journal of experimental & clinical cancer research : CR.

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

E. Koritáková, H. Klamová, J. Horáček, 2019, Blood.

The Morphology of Cell Differentiation, Terminal Differentiation and Ageing Seems To Reflect the Same Process: a Short Note.

K. Smetana, D. Mikulenková, H. Klamová, 2021, Folia biologica.

Predictive value of serum cytokine levels in chronic myeloid leukemia patients.

H. Klamová, V. Vonka, M. Petráčková, 2016, Immunology letters.

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells

H. Klamová, J. Březinová, Š. Ransdorfová, 2021, bioRxiv.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types

H. Klamová, J. Mayer, Z. Ráčil, 2011, Leukemia & lymphoma.

MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?

H. Klamová, J. Moravcová, Tereza Lopotová, 2011, Leukemia research.

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain.

H. Klamová, J. Moravcová, K. Polakova, 2008, Leukemia research.

The cell body space occupied by the nucleus during the cell differentiation in human lymphocytic, granulocytic and erythroid cell lineages.

K. Smetana, D. Mikulenková, H. Klamová, 2021, Physiological research.

Hsp90 - a potential prognostic marker in CML.

H. Klamová, J. Moravcová, D. Moučková, 2013, Blood cells, molecules & diseases.

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

S. Mustjoki, H. Klamová, F. Mahon, 2023, Leukemia.

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

S. Mustjoki, T. Brümmendorf, H. Klamová, 2019, Blood.

Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy

M. Baccarani, S. Paolini, G. Rosti, 2013 .